XIAP and breast carcinoma: The strengths of our study include the size of the series, which to our knowledge represents the largest prognostic/predictive study of XIAP expression reported so far in breast cancer, the analysis per molecular subtype, the independent prognostic and predictive values, and analysis at both mRNA and protein levels.